Our product portfolio features leading products that address a variety of diseases, including rheumatology, auto-immune disease, pediatrics, and specialty oncology
View Product Portfolio
*Percentages are of the Company’s revenue as disclosed in the condensed interim consolidated statements of loss and comprehensive income (unaudited) of the Company for the nine-month period ended December 31, 2019, as filed on SEDAR, plus the pro-forma impact of Ixinity, as if the acquisition had been completed at the beginning of the fiscal year.
In addition to driving organic growth through sales of products within our existing portfolio, we are actively growing our product portfolio through new product launches, new product licensing and acquisitions.
We continuously look to license or acquire new products and solutions aimed at addressing the essential needs of consumers, patients and health care partners, leveraging our North American sales force and infrastructure.
Canada
USA
